3
Nov
2017
Amazon Prowling the Drug Supply Chain, Celgene’s Ho-Hum Bounceback & a Couple More IPOs
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
30
Oct
2017
Atlas, Amgen, Lilly Bet $30M for Kymera’s Imaginative Protein Degradation
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
27
Oct
2017
Activist FDA Boss Zeroes in on Opioid Crisis, PTC Shot Down, and CRISPR 2.0 Buzz
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
26
Oct
2017
VIDEO: Climbing Mount Everest to Support Cancer Research at Fred Hutch
Hi, I’m Luke Timmerman, a biotech journalist. I’m carrying my 80-pound training backpack, up and down the hills of Seattle, for a reason. I’m training to climb Mt. Everest, the highest mountain in the world, in 2018. Why do this? Of course, I love the mountains. But mostly, I’m doing it to support the top-notch research at the Fred Hutchinson... Read More
25
Oct
2017
Richard Pops on Fighting the Opioid Painkiller Crisis
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
24
Oct
2017
AbbVie Shells Out $205M Upfront for Alector’s Antibodies Vs. Alzheimer’s
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
23
Oct
2017
BioMarin Book Contains Rare Insight Into the Rare Disease Business
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
20
Oct
2017
Gilead’s Thrilling CAR-T Victory, Celgene’s Agonizing Crohn’s Defeat, & Vir Goes Big
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
18
Oct
2017
Vir Biotechnology, a ‘Shock and Awe’ Startup, Bets on Infectious Disease with $500M+
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
17
Oct
2017
VC Briefs: Gemini’s $42M for Dry AMD & Mission Bio’s $10M for Single-Cell Analysis
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
16
Oct
2017
Exclusive: Illumina Ventures Rakes in $230M Fund, Declares Independence from Parent, Mostly
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
13
Oct
2017
Spark Gene Therapy Sails Thru AdComm, Broad Institute Nuzzles Up to Deerfield, Pfizer’s Cancer Deal in Africa
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
11
Oct
2017
George Yancopoulos on Threading the Price Needle, and Building a Biotech to Last
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
9
Oct
2017
Where Does Alzheimer’s R&D Go Now? Plenty of Directions
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
6
Oct
2017
IPO Market Finds a Rhythm, FDA Huddles with FTC on Pricing, & Praluent Gets to Stay
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
3
Oct
2017
Nimbus Rinses and Repeats, Enticing Celgene With Immunology Drug Candidates
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
2
Oct
2017
KSQ Scores $76M, Lures Meeker to CRISPR Dream of ‘High Confidence Drug Development’
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
27
Sep
2017
The Long Run Ep. 2: Editas Medicine CEO Katrine Bosley
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
25
Sep
2017
Socializing After Hours: It’s How Biotech Runs, and Should Be Open to All
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
22
Sep
2017
Alnylam Gets Over the Hump, Nabriva Nails Antibiotic Trial & Biosimilar Avastin Arrives
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.